Immunosuppressants - Philippines

Philippines

The Immunosuppressants market in the Philippines is expected to achieve a revenue of US$53.49m by 2024.
Furthermore, it is projected to experience an annual growth rate (CAGR 2024-2029) of 16.32%, leading to a market volume of US$113.90m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$35,470.00m in 2024.
The demand for immunosuppressants in the Philippines is steadily rising due to an increasing number of organ transplant surgeries in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Immunosuppressants in the Philippines has been on the rise in recent years.

Customer preferences: The increase in demand for Immunosuppressants in the Philippines can be attributed to the growing number of patients with autoimmune diseases, such as lupus and rheumatoid arthritis. These patients require medication to suppress their immune system and prevent it from attacking their own body.

Trends in the market: The Immunosuppressants market in the Philippines is expected to continue to grow in the coming years due to the increasing prevalence of autoimmune diseases in the country. Additionally, the availability of generic Immunosuppressants is also contributing to the growth of the market as it makes the medication more affordable for patients.

Local special circumstances: One unique aspect of the Immunosuppressants market in the Philippines is the high cost of branded medications. This has led to a preference for generic medications among patients, which has further fueled the growth of the market.

Underlying macroeconomic factors: The Philippines has a growing economy and an expanding healthcare sector, which is contributing to the growth of the Immunosuppressants market. Additionally, the government has implemented policies to improve access to healthcare for all Filipinos, which has led to an increase in the number of patients seeking treatment for autoimmune diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.